|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-8-13
|
|
pubmed:abstractText |
To determine the efficacy, safety and pharmacokinetics of infliximab dose escalation in patients with rheumatoid arthritis (RA) who had an inadequate response to 3 mg/kg infliximab treatment or whose disease flared after initially responding.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0003-4967
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1233-8
|
|
pubmed:dateRevised |
2010-9-2
|
|
pubmed:meshHeading |
pubmed-meshheading:17392352-Adult,
pubmed-meshheading:17392352-Antibodies,
pubmed-meshheading:17392352-Antibodies, Monoclonal,
pubmed-meshheading:17392352-Arthritis, Rheumatoid,
pubmed-meshheading:17392352-Chi-Square Distribution,
pubmed-meshheading:17392352-Disease Progression,
pubmed-meshheading:17392352-Double-Blind Method,
pubmed-meshheading:17392352-Drug Administration Schedule,
pubmed-meshheading:17392352-Female,
pubmed-meshheading:17392352-Humans,
pubmed-meshheading:17392352-Immunosuppressive Agents,
pubmed-meshheading:17392352-Joints,
pubmed-meshheading:17392352-Male,
pubmed-meshheading:17392352-Middle Aged,
pubmed-meshheading:17392352-Recurrence,
pubmed-meshheading:17392352-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis.
|
|
pubmed:affiliation |
Centocor Research and Development, Inc, Malvern, PA, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
